Viatris
Markets established brands, complex generics, and newer innovative medicines worldwide.
Something off on this page? Send us feedback.
Profile
Markets established brands, generic and complex generic medicines, and a developing portfolio of innovative drugs through four geographic businesses. Revenue spans developed and emerging markets, while approvals, regulated pricing, manufacturing quality, and reliable supply shape results.
Markets branded medicines, generic and complex generic drugs, and a developing set of patent-protected products across cardiovascular, infectious disease, respiratory, central nervous system, and other therapeutic areas. Established brands such as Lipitor, Norvasc, Lyrica, Viagra, EpiPen, and Creon sit alongside higher-volume generics and complex products including inhaled and injectable therapies. Sales are managed through Developed Markets, Greater China, JANZ, and Emerging Markets.
Uses an integrated research, regulatory, manufacturing, supply-chain, and commercial platform to launch and distribute medicines in more than 165 countries and territories. Portfolio simplification divested the owned biosimilars platform, most consumer health, women's health, and Indian active-ingredient operations, while investment shifted toward limited-competition generics, value-added medicines, and innovative brands. Performance depends on drug approvals, regulated pricing and reimbursement, patent and exclusivity cycles, manufacturing compliance, and reliable global supply.
Company facts
Key statistics
Year to date +31.1% · Average volume (30d) 9.6M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| May 19, 2026 | Barclays | Reiterate | Overweight | $15 | $22 | |
| May 8, 2026 | Truist Financial | Target | $16 | $20 | ||
| Feb 9, 2026 | UBS | Target | $12 | $18 | ||
| Jan 28, 2026 | Piper Sandler | Reiterate | Neutral | $13 | $12 | |
| Jan 16, 2026 | Argus Research | Upgrade | Hold | Buy | $15 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | $0.60 | $0.69 | +14.8% | $3.68B | $3.76B | +2.2% | −7.71% |
| May 7, 2026Q1 FY26 | $0.52 | $0.59 | +13.5% | $3.36B | $3.52B | +4.8% | −1.27% |
| Feb 26, 2026Q4 FY25 | $0.53 | $0.57 | +7.1% | $3.53B | $3.70B | +4.8% | −2.10% |
| Nov 6, 2025Q3 FY25 | $0.62 | $0.67 | +7.9% | $3.62B | $3.76B | +3.8% | +0.10% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.25B | $3.58B | $3.76B | $3.70B | $3.52B | $3.76B | |
| Gross profit | $1.16B | $1.33B | $1.38B | $1.13B | $1.16B | $1.46B | |
| Operating income | −$2.88B | $233.0M | $251.6M | −$265.5M | −$79.7M | $6.3M | |
| Net income | −$3.04B | −$4.6M | −$128.2M | −$340.1M | $176.4M | −$118.8M | |
| Diluted EPS | −$2.55 | −$0.00 | −$0.11 | −$0.30 | $0.15 | −$0.10 | |
| Gross margin | 35.7% | 37.2% | 36.8% | 30.6% | 32.9% | 38.8% | |
| Operating margin | -88.6% | 6.5% | 6.7% | -7.2% | -2.3% | 0.2% |
Fiscal years (4-quarter sums)FY21 $17.89B · FY22 $16.26B · FY23 $15.43B · FY24 $14.74B · FY25 $14.30B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.51B · Total debt $13.63B · Total assets $35.04B · Shareholders' equity $14.26B
Dividends
Raised for 4 straight years — most recently to $0.12 from $0.11 in Feb 2022. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 21, 2026 | Aug 21 | Sep 16 | $0.12 | |
| May 22, 2026 | May 22 | Jun 17 | $0.12 | |
| Mar 9, 2026 | Mar 9 | Mar 18 | $0.12 | |
| Nov 24, 2025 | Nov 24 | Dec 15 | $0.12 | |
| Aug 22, 2025 | Aug 22 | Sep 15 | $0.12 | |
| May 23, 2025 | May 23 | Jun 16 | $0.12 | |
| Mar 10, 2025 | Mar 10 | Mar 18 | $0.12 | |
| Nov 22, 2024 | Nov 22 | Dec 13 | $0.12 |
Ownership
Shares outstanding 1.16B · Float 1.15B · 98.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 96.66M | 8.30% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 86.02M | 7.39% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 76.05M | 6.53% | 13F | Aug 13, 2026 |
| Davis Selected Advisers | 75.23M | 6.46% | 13F | Aug 11, 2026 |
| T. Rowe Price Associates, Inc. | 74.72M | 6.30% | 13G | May 14, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 25, 2026 | Paul Campbell | officer: See Remarks | −50,076 | $16.17 |
| Mar 23, 2026 | Paul Campbell | officer: See Remarks | −21,350 | $13.28 |
| Aug 27, 2025 | David S. Simmons | director | +286 | $10.42 |
| Nov 3, 2025 | David S. Simmons | director | +213 | $10.43 |
| Sep 11, 2025 | Corinne le Goff | officer: Chief Commercial Officer | −7,032 | $10.25 |
Peers
- Teva (ADR)
Broad global peer in generics, biosimilars, and selected brands
- Organon
Established-brand and biosimilar peer with mature-product exposure
- Dr. Reddy's Laboratories (ADR)
Global generics and branded-generics rival with U.S. scale
- Amneal Pharmaceuticals
U.S. generics peer across retail, injectables, and biosimilars
- Bausch + Lomb
Ophthalmology peer across dry eye and eye-care pharmaceuticals
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Viatris | $16.30 | −0.23% | $19.03B | — | 6.4 | 1.3 | +4.9% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Organon | $13.76 | 0.00% | $3.61B | 17.9 | 3.9 | 0.6 | −2.3% |
| Dr. Reddy's Laboratories (ADR) | $12.18 | 0.00% | $10.15B | 29.2 | 32.5 | 3.0 | −16.2% |
| Amneal Pharmaceuticals | $17.54 | 0.00% | $5.60B | 36.0 | 16.9 | 1.8 | +9.9% |
| Bausch + Lomb | $17.15 | 0.00% | $6.13B | — | 17.2 | 1.2 | +9.1% |
| Median | 32.6 | 16.9 | 1.8 | −0.8% |